Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANEŽ (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.
Posted over 1 year ago
Nanocrystals make dentures shine
Research team develops advanced live-imaging approach (w/ video)
Tunable nano-suspensions for light harvesting
Tagging tumors with gold: Scientists use gold nanorods to flag brain tumors
Laser Hardware/Control Software Engineer I (209) - Hanscom AFB, MA
Postdoctoral Position - La Jolla, CA
Research Engineer position in Super-resolution microscopy - Castelldefels (Barcelona), Spain
Physicist/Physical Chemist/Research Engineer (We Sponsor Clearances) - Lexington, MA
AACR 103rd Annual Meeting 2012
Conference on Lasers and Electro-Optics and the...
